{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:07:32Z","timestamp":1779084452324,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Clin. Diabetes Healthc."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the impact of a gene polymorphism-based individualized nursing strategy on the efficacy of semaglutide in overweight type 2 diabetes (T2DM) patients and to assess its role in mitigating genotype-driven outcome disparities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighty-three overweight T2DM patients initiating semaglutide were enrolled. The TCF7L2 rs7903146 polymorphism was detected via PCR-RFLP. Patients were stratified into a genetically advantageous group (Group A, CC genotype, n=49) and a non-advantageous group (Group B, CT\/TT genotypes, n=34). Both groups received standard semaglutide therapy and routine care for the first month. Subsequently, Group B received a tailored, optimized nursing intervention for two additional months, while Group A continued routine care. Glycemic control, body weight, adverse events, and satisfaction were compared at baseline, 1 month, and 3 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At 1 month, Group A showed superior reductions in fasting glucose, HbA1c, weight, and BMI compared to Group B (all P&amp;lt;0.05), with a higher composite target achievement rate (93.94% vs. 84.00%, P&amp;lt;0.05). After Group B received the optimized strategy, between-group differences in all efficacy parameters became non-significant by 3 months (P&amp;gt;0.05). Group B also demonstrated a significantly lower rate of gastrointestinal adverse reactions (11.76% vs. 28.57%, P&amp;lt;0.05) and higher nursing satisfaction (97.06% vs. 81.63%, P&amp;lt;0.05) at the study endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TCF7L2 CC genotype patients respond more rapidly to semaglutide. Implementing a genotype-informed optimized nursing strategy for CT\/TT carriers after the first month reduces the initial efficacy gap, leading to similar outcomes by 3 months while improving tolerability and patient satisfaction. This approach merits further prospective evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcdhc.2026.1815726","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:40:15Z","timestamp":1779082815000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimization of nursing strategies for semaglutide treatment in overweight type 2 diabetes based on gene polymorphism"],"prefix":"10.3389","volume":"7","author":[{"given":"Xing","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaoqing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Guo","sequence":"additional","affiliation":[{"name":"AI and Omics Research Center, AigenX Biosciences Co., Ltd.","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01067-0","article-title":"Managing early-onset type 2 diabetes in the individual and at the population level","volume":"405","author":"Misra","year":"2025","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.22208","article-title":"Prevalence and treatment of diabetes in China, 2013-2018","volume":"326","author":"Wang","year":"2021","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nature05482","article-title":"Mechanisms linking obesity to insulin resistance and type 2 diabetes","volume":"444","author":"Kahn","year":"2006","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01114-y","article-title":"Insulin resistance in type 2 diabetes mellitus","volume":"21","author":"Accili","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1\u20137 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.51","article-title":"Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery","volume":"12","author":"Zhou","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1484","article-title":"Diabetes: Is there a future for pharmacogenomics guided treatment","volume":"106","author":"Pearson","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ng1732","article-title":"Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes","volume":"38","author":"Grant","year":"2006","journal-title":"Nat Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M706105200","article-title":"Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation","volume":"283","author":"Liu","year":"2008","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30706","article-title":"Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes","volume":"117","author":"Lyssenko","year":"2007","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddp178","article-title":"Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function","volume":"18","author":"Shu","year":"2009","journal-title":"Hum Mol Genet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1307-x","article-title":"The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men","volume":"52","author":"Pilgaard","year":"2009","journal-title":"Diabetologia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1169","article-title":"TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action","volume":"59","author":"Villareal","year":"2010","journal-title":"Diabetes"},{"key":"B20","doi-asserted-by":"publisher","first-page":"894","DOI":"10.2337\/db08-1187","article-title":"TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells","volume":"58","author":"da Silva Xavier","year":"2009","journal-title":"Diabetes"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ng.120","article-title":"Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes","volume":"40","author":"Zeggini","year":"2008","journal-title":"Nat Genet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2337\/diaclin.34.2.70","article-title":"Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics","volume":"34","author":"Powers","year":"2016","journal-title":"Clin Diabetes"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.221","article-title":"Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine","volume":"95","author":"Crettol","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13075","article-title":"Personalized medicine in diabetes: the role of 'omics' and biomarkers","volume":"33","author":"Pearson","year":"2016","journal-title":"Diabetes Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.2337\/dc23-S006","article-title":"6. Glycemic targets: Standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61994-2","article-title":"Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.15.1641","article-title":"Self-management education programs in chronic disease: a systematic review and methodological critique of the literature","volume":"164","author":"Warsi","year":"2004","journal-title":"Arch Intern Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1037\/hea0000131","article-title":"Distress and type 2 diabetes-treatment adherence: a mediating role for perceived control","volume":"34","author":"Gonzalez","year":"2015","journal-title":"Health Psychol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/1077558712465774","article-title":"Patient-centered care and outcomes: a systematic review of the literature","volume":"70","author":"Rathert","year":"2013","journal-title":"Med Care Res Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1651","article-title":"The Clinical Pharmacogenetics Implementation Consortium: 10 years later","volume":"107","author":"Relling","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3632","article-title":"Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin","volume":"48","author":"Zhou","year":"2016","journal-title":"Nat Genet"}],"container-title":["Frontiers in Clinical Diabetes and Healthcare"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2026.1815726\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:40:15Z","timestamp":1779082815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2026.1815726\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":32,"alternative-id":["10.3389\/fcdhc.2026.1815726"],"URL":"https:\/\/doi.org\/10.3389\/fcdhc.2026.1815726","relation":{},"ISSN":["2673-6616"],"issn-type":[{"value":"2673-6616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"article-number":"1815726"}}